Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:B-cell lymphoma 2 inhibitor
go back to main search page
Accession:CHEBI:133022 term browser browse the term
Definition:Any inhibitor of B-cell lymphoma 2 protein.
Synonyms:related_synonym: B-cell lymphoma 2 inhibitors;   Bcl-2 inhibitor;   Bcl-2 inhibitors
 xref: Wikipedia:Bcl-2


show annotations for term's descendants           Sort by:
 
ABT-737 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]] CTD PMID:32802178 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bag3 BAG cochaperone 3 decreases response to substance
multiple interactions
ISO BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]
CTD PMID:23341456 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding
multiple interactions
ISO ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]
CTD PMID:17097560 PMID:17200714 PMID:21880625 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
ISO ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]
BCL2 protein modified form results in decreased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression
ISO ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]
ABT-737 results in increased expression of BCL2L1 protein alternative form
CTD PMID:18628207 PMID:19060243 PMID:21256112 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases response to substance
ISO [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Becn1 beclin 1 multiple interactions ISO ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:18628207 PMID:32061152 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein CTD PMID:20104024 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO ABT-737 results in increased cleavage of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]
ABT-737 results in increased activity of CASP3 protein
CTD PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity ISO ABT-737 results in increased activity of CASP7 protein CTD PMID:20038611 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 increases cleavage
multiple interactions
ISO ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]
CTD PMID:20104024 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 increases activity
increases cleavage
multiple interactions
ISO ABT-737 results in increased activity of CASP9 protein
ABT-737 results in increased cleavage of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]
CTD PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Krt18 keratin 18 increases cleavage ISO ABT-737 results in increased cleavage of KRT18 protein CTD PMID:19010845 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance
multiple interactions
ISO MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]
CTD PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 PMID:32802178 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions
decreases expression
ISO [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein
CTD PMID:19773376 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Nanog Nanog homeobox decreases expression ISO ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases response to substance ISO PMAIP1 protein results in increased susceptibility to ABT-737 CTD PMID:17688235 NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] CTD PMID:21880625 NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein] CTD PMID:20104024 PMID:32061152 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Usp7 ubiquitin specific peptidase 7 multiple interactions ISO USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr10:6,880,684...6,925,033
Ensembl chr10:6,828,795...6,925,355
JBrowse link
navitoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAK1 protein CTD PMID:21652541 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAX protein CTD PMID:21652541 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
ISO navitoclax results in decreased expression of BIRC5 protein
[MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
CTD PMID:28947240 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO navitoclax results in increased cleavage of CASP3 protein
[navitoclax co-treated with Vorinostat] results in increased activity of CASP3 protein
CTD PMID:21562047 PMID:21652541 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases cleavage ISO navitoclax results in increased cleavage of CASP9 protein CTD PMID:21562047 PMID:28947240 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Gsn gelsolin increases cleavage ISO navitoclax results in increased cleavage of GSN protein CTD PMID:21562047 NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
JBrowse link
G Mtor mechanistic target of rapamycin kinase affects response to substance
multiple interactions
ISO MTOR protein affects the susceptibility to navitoclax
[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein
CTD PMID:28947240 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein
navitoclax results in increased cleavage of PARP1 protein
CTD PMID:28947240 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 affects binding ISO venetoclax binds to ABCG2 protein CTD PMID:33954893 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases activity ISO venetoclax results in decreased activity of BCL2 protein CTD PMID:26214592 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [YM 155 co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP3 protein CTD PMID:31837377 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
multiple interactions
ISO venetoclax results in increased expression of MCL1 protein
[YM 155 co-treated with venetoclax] results in decreased expression of MCL1 protein
CTD PMID:31837377 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of PARP1 protein CTD PMID:31837377 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19821
    role 19769
      biological role 19769
        biochemical role 19389
          B-cell lymphoma 2 inhibitor 31
            ABT-737 26
            navitoclax 8
            venetoclax 7
paths to the root